Title
Category
Credits
Event date
Cost
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma?
  • Hodgkin Lymphoma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
Given the high cure rate of classic Hodgkin lymphoma, clinical trials strive to reduce potential long-term toxicities of treatment. Novel agents such as antibody-drug conjugates and immune checkpoint inhibitors have become part of front-line treatment recommendations for advanced stage classic Hodgkin lymphoma over the last several years, allowing for reduction in toxicities such as pulmonary toxicity associated with bleomycin and secondary cancer risk from agents such as procarbazine.
The Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
$0.00
The treatment landscape for relapsed/refractory Hodgkin lymphoma has changed significantly in recent years with the incorporation of novel agents such as brentuximab vedotin and the checkpoint inhibitors nivolumab or pembrolizumab. Second-line and subsequent therapy decisions are complex and must take into account multiple factors, such as use of novel agents in the frontline setting and the potential unique toxicities of novel agents.
Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
08/14/2025
$0.00
With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, understanding the toxicities associated with these agents, and providing patient education.